Type 1 Diabetes TrialNet
Study Participants Healthcare Professionals Researchers Locations Publications What is TrialNet? News and Events Get Screened! Home
TrialNet News and Events
Type 1 Diabetes - TrialNet e-news - Spring 2011

NEW STUDIES

Aided by relatives of those with type 1 diabetes, TrialNet researchers close in on prevention
Clinical trials have shown that new drugs are able to slow the progression of diabetes in people who have already been diagnosed with the disease. Preventing the disease is the next big step, and according to Kevan Herold, M.D., TrialNet principal investigator and professor of immunobiology and medicine at Yale, "We are attempting to take that step now, and it’s the relatives of those with type 1 diabetes who will make it possible." Go

STUDY FINDINGS AND UPDATES

Oral Insulin Prevention Study surpasses midway enrollment goal - Thousands more need to be screened
With 220 participants, the Oral Insulin Prevention Study recently surpassed the halfway mark to its anticipated enrollment goal. However, thousands more people will need to be screened to enroll the 100 to 200 more study participants who are needed. That’s because only four or five people out of every 100 screened will actually have type 1 diabetes autoantibodies, and even a smaller number will have the specific autoantibodies needed for this study. Go


Twins around the country support TrialNet research
Of the thousands of families supporting TrialNet research, many include twins. As one would expect, twins share more than an obvious outward appearance. Twins share genes and can share risk for type 1 diabetes. Go



 

New onset study meets enrollment goal in record time
Just 5 months after opening, the Canakinumab (Anti IL-1 Beta) Study for people newly diagnosed with type 1 diabetes met its enrollment goal of 66 participants. The study is testing whether repeated injections of an experimental drug called canakinumab will help people with newly-diagnosed type 1 diabetes continue to make some of their own insulin. Canakinumab is approved by the Federal Drug Administration (FDA) for rare inflammatory diseases. Go


 

TrialNet studies currently enrolling
Natural History Study of the Development of Type 1 Diabetes: Screening and observing relatives of people with type 1 diabetes to learn more about how the disease occurs.

Oral Insulin for Prevention of Type 1 Diabetes Study: Testing whether a daily oral insulin capsule can prevent or delay type 1 diabetes in at-risk relatives of people with the disease.

Anti-CD3 Prevention Study: Testing whether teplizumab can stop or slow down the autoimmune reaction that is destroying beta cells in people who are at high risk of developing type 1 diabetes.

Metabolic Control in New Onset Diabetes: Studying whether early intensive glucose control can help preserve insulin production.

Photo of family

TrialNet COMMUNITY

TrialNet call for videos - Tell the world your TrialNet story
Every day TrialNet staff members hear wonderful stories from study participants, and now we’d like your help to share those stories through video. This is your chance to tell the world why TrialNet research is important to you and encourage other families who have a relative with type 1 to get involved in research. Go


Photo of twins

TrialNet pays tribute to Dr. Mark Pescovitz
The world lost a dedicated physician, researcher, transplant surgeon, accomplished artist, humanitarian, and friend last December when Mark Pescovitz, M.D., was killed in a tragic automobile accident. Dr. Pescovitz was a TrialNet principal investigator at Indiana University, where he was the professor and vice chair for research in the Department of Surgery, professor of microbiology and immunology, and director of the Transplant Immunology Laboratory. Go

Photo of family

DID YOU KNOW?

TrialNet goes to camp
The Diabetes Education and Camping Association (DECA), which represents diabetes camps worldwide, is partnering with TrialNet to offer risk screening for family members of campers with type 1 diabetes. For a list of participating camps and screening dates and times, visit the TrialNet Facebook page: www.facebook.com/diabetestrialnet. To find a diabetes camp near you, visit the DECA website: www.diabetescamps.org


Facebook

Follow TrialNet on Facebook for regular news and updates!

www.facebook.com/diabetestrialnet


 

TrialNet risk screening available virtually anywhere
TrialNet risk screening is available at nearly 200 sites across the United States or anywhere via mail. You can find a TrialNet screening location by completing the online screener. To request a test kit by mail, just contact one of our clinical centers listed here. The test kit can be taken to a local doctor’s office or lab to collect a blood sample for analysis by TrialNet’s lab. Risk screening is available at no charge to those who are:

  1. Age 45 and younger who have a parent, sibling, or child with type 1 diabetes, or
  2. Age 20 and younger who have a niece, nephew, aunt, uncle, grandparent, half-sibling or cousin with type 1 diabetes.

Join TrialNet in the fight against type 1 diabetes!

Here's how YOU can help:

  • If you have a relative with type 1 diabetes, find out if you are eligible for screening; if you are, get involved and get your family screened
  • Forward TrialNet E-News to family members and friends who might be interested
  • Share this information on your MySpace or Facebook page
  • Follow TrialNet on Facebook